Conestoga Capital Advisors, LLC on Stevanato Group S.p.A.
Thesis
Stevanato is shifting toward higher-value pharmaceutical containment and drug-delivery products, particularly for biologic treatments and GLP-1 medicines. High-value solutions grew 16% and contributed to improving product mix and EBITDA margins. Investments in manufacturing capacity in the U.S. and Italy should enable the company to address increasing demand for premium injectable delivery systems. Conestoga sees sustained growth and profitability potential as this mix shift develops.
“High-value solutions grew 16% in 2Q, and an improving product mix contributed to margin expansion”
Key risks
- Manufacturing capacity expansions in the U.S. and Italy may be costly or take time to ramp.
- Premium valuation multiples remain sensitive to higher Treasury yields.
- Growth depends on continued demand for biologics and GLP-1 delivery systems.